OR WAIT null SECS
June 4, 2015.
honored the Genentech-Seragon and Regeneron-Avalanche partnerships at the
Allicense 2015 Breakthrough Award for Deals of the Year
in San Francisco last month. Genentech Partnering and Seragon won in the M&A category for their $725 million deal around breast cancer therapies, while Regeneron and Avalanche picked up their award for Biopharmaceutical Licensing Deal of the Year for their collaboration on gene therapy for ophthalmologic diseases. Thomson Reuters analysts used its Thomson Reuters Recap tool to examine hundreds of deals negotiated in 2014 to nominate five contenders in both award categories, backed by data in Cortellis Competitive Intelligence. The nominations were then put to a public vote by the biopharmaceutical community to accurately identify the most influential deals executed in 2014.